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August 16, 2005:730–42pproximately 0.30 for LVM in the Framingham Heart Study.
nalyzing data among hypertensive siblings, the HyperGEN
tudy found that African American subjects had higher sibling
orrelation in LVM compared with white subjects (11) but that
hite subjects had a higher correlation in RWT than did African
merican subjects. However, no heritability was presented in their
tudy.
Unlike most previous studies, we assessed the heritability of
VM after correction by the three most commonly used indices of
ody size. The estimates of heritability of LVM were not signif-
cantly affected by the type of indexing chosen, especially for model
, with the greatest number of covariates (Table 1). This observa-
ion suggests that no single body size index appears preferable in
tudies on adult populations similar to ours. Adjustment for
ovariates other than body size, age, and gender had almost no
nfluence on estimates of heritability in models 2 and 3.
More than 40% of our subjects were hypertensive, and 34.5%
ere taking antihypertensive medication. In our models, adjusting
or SBP and antihypertensive medication did not appreciably
nfluence the estimates of heritability after accounting for age,
ender, weight, and height. Furthermore, excluding all partici-
ants taking antihypertensive medications had little effect on
eritability estimations, although it yielded less significant p
alues (data not shown). Therefore, the effect of hypertension
nd antihypertensive medication may not be substantial in our
tudy.
In summary, our study indicated that significant genetic factors
nfluence the familial resemblance of LVM in the Caribbean
ispanic population. The considerable estimates of heritability
rovide the basis for our long-term goal of NOMAFS to map and
etect genetic variants contributing to LVM and its related
henotypes.
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etters to the Editor
atent Foramen Ovale/Atrial
eptal Defect Closure and Migraine:
earching the Rationale for the Procedure
zarbal et al. (1) studied closing patent foramen ovale (PFO) or
trial septal defect (ASD) for prophylaxis of migraine. The
ccompanying editorial highlights areas of caution (2). Additional
oncerns are: 1) Both right-to-left shunt (PFO) and left-to-right
hunt (ASD) appear associated with migraine (3). 2) Closure of
SD improves left ventricular stroke volume; this physiological
ariable (3) might be involved in precipitating daily migraines. 3)
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August 16, 2005:730–42ollowing ASD closure, plasma atrial natriuretic peptide levels
ould decrease (3). 4) Lateralization of headaches is a character-
stic feature of migraine (4). With the concept of paradoxical
mbolization of gas, thrombi, or vasoactive neuromediators (2),
hese potential precipitants are presumed to be streamed regularly
ver decades to the same brain parenchymal site or circulatory
egment in order to produce lateralizing headache (5). This is
ighly unlikely as paradoxical emboli are generally directed ran-
omly. 5) Atenolol—a first-line migraine prophylactic—does not
eadily cross the blood-brain barrier (BBB) or significantly influ-
nce either brain neuronal function or circulation (4). 6) Drugs
sed to manage patients with migraine aura such as nifedipine,
urosemide, and verapamil do not readily cross the intact BBB (6).
hese pharmacological absolutes challenge prevalent concepts of
rimary involvement of brain in migraine. 7) For a disease that can
ontinue for decades, a follow-up period of 12 months (1) is rather
hort.
An explanation is required for the characteristic late appearance
in the teens or twenties) or disappearance (second and third
rimesters of pregnancy and in later decades), in general, of
igraine despite continued presence of PFO/ASD. Second, a high
ncidence of right-to-left shunt has been seen in cluster headache
atients (42.5%, 17 of 40) (7). Cluster headache is a strictly
ateralized primary headache; brain ischemia is not implicated in its
athogenesis. Third, migraine-with-aura patients seem to respond
ar better than migraine-without-aura patients (1). Headaches are
ess frequent, less severe, and shorter in migraine-with-aura pa-
ients. When the frequency of headache attacks is lessened, the
ossibility of the placebo effect in migraine trials is greater (5).
At this juncture, it is necessary to weigh carefully whether we
eed more reflection about the basic issues surrounding the
pparent link between migraines and PFO/ASD or more clinical
rials.
Vinod Kumar Gupta, MD
Dubai Police Medical Services
.O. Box 12005
ubai
nited Arab Emirates
-mail: docgupta@emirates.net.ae
doi:10.1016/j.jacc.2005.05.029
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he letter to the editor by Dr. Gupta raises some concerns, and it
uestions the validity of our hypothesis, which attempts to explain the
bserved connection between interatrial shunts and migraine head-
ches (1). It is appropriate to be skeptical of any new proposition,
specially one that “rocks the boat” of currently accepted beliefs. We
ubmit that there are enough independent observations of an associ-
tion between patent foramen ovale (PFO) closure and significant
eduction in migraine headache to allow this proposal a chance by
erforming a randomized clinical trial.
The clinical observation has been made that patients who have
n interatrial communication 1) have an increased incidence of
igraine headaches, and 2) closure of the interatrial communica-
ion results in significant improvement of the migraines. Although
hese studies are limited by their retrospective nature and a cohort
hat may not be reflective of the overall population of patients with
igraine headache, the compelling findings of these studies have
aised the possibility that closure of interatrial communications
ight provide a substantive treatment for migraine headaches.
Our hypothesis is that migraine headaches occur in people with
susceptible neuronal substrate. Several types of triggers might
nduce a migraine, but some of them may be chemically mediated,
ither through ingestion, or endogenously produced. Passing
hrough the venous system, these chemicals are usually detoxified
r perhaps just diluted in a first passage through the lungs.
owever, if a PFO or atrial septal defect (ASD) is present, then
he intermittent right-to-left shunt that occurs with straining in
ither entity may permit these chemicals to enter the cerebral
irculation in a high concentration and trigger the neurologic
onstellation that is recognized as a migraine headache. We agree
ith Dr. Gupta that emboli are unlikely to be the trigger of
igraine headaches.
This hypothesis does not explain the mechanism of all migraine
eadaches. We do not understand why patients who have migraine
ith aura respond more frequently to PFO closure than do patients
ho have migraine without aura. These fascinating observations
ay open more avenues for research that might produce more
uccessful therapeutic options for migraine sufferers than do
urrent medical regimens.
With 12% of the population suffering from migraine headaches,
e understand why the observations of reduction in migraine
eadaches following closure of interatrial shunts may generate
nterest and controversy. As with any new theory, the observations
hat support the theory come long before the randomized con-
rolled trial that will test its validity. Our study supports the
bservations from other independent centers and provides a
heoretical construct that “connects the dots” of rather disparate
ieces of data. Let us turn the question around. How does one
xplain these independent observations of decreased headache
ollowing PFO closure? Placebo? This is unlikely when five
ndependent centers all describe similar observations. Of the
atients with migraine and aura, 75% had complete resolution of
heir headaches, with some patients followed up to three years.
here is no drug or placebo that reports such a dramatic and
ong-lasting benefit to reduce migraine pain.
Finally, there are valid concerns with implanting a permanent
evice in someone’s heart, especially when the indication is not
ife-threatening. We should use the observations of the studies as
starting point to generate a hypothesis and then perform aandomized clinical trial that will assess the potential benefits and
